federal_register: 2014-02755

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
2014-02755 Serious Drug-Induced Liver Injury: Who Gets It? Who Doesn't? Why?; Public Conference; Request for Comments Notice The Food and Drug Administration (FDA) is announcing a public conference entitled "Serious Drug-Induced Liver Injury (DILI): Who Gets It? Who Doesn't? Why?" This conference will be cosponsored with the Critical Path Institute (C-Path) and the Pharmaceutical Research and Manufacturers of America. Its purpose is to discuss, debate, and share views among stakeholders in the pharmaceutical industry, academia, health care providers, patient groups, and regulatory bodies on how best to detect and assess the severity, extent, and likelihood of drug causation of liver injury and dysfunction in people using drugs for any medical purpose. 2014-02-10 2014 2 https://www.federalregister.gov/documents/2014/02/10/2014-02755/serious-drug-induced-liver-injury-who-gets-it-who-doesnt-why-public-conference-request-for-comments https://www.govinfo.gov/content/pkg/FR-2014-02-10/pdf/2014-02755.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA) is announcing a public conference entitled "Serious Drug-Induced Liver Injury (DILI): Who Gets It? Who Doesn't? Why?" This conference will be cosponsored with the Critical Path Institute (C-Path) and the...

Links from other tables